Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H19NO3S2 |
Molecular Weight | 325.446 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2
InChI
InChIKey=UQWLOWFDKAFKAP-WXHSDQCUSA-N
InChI=1S/C15H19NO3S2/c1-10(9-20)14(17)16-8-12(7-13(16)15(18)19)21-11-5-3-2-4-6-11/h2-6,10,12-13,20H,7-9H2,1H3,(H,18,19)/t10-,12+,13+/m1/s1
Molecular Formula | C15H19NO3S2 |
Molecular Weight | 325.446 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) |
10.9 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOPRANOL Approved UseZOPRANOL is indicated for the treatment of mild to moderate essential hypertension. Launch Date9.6465597E11 |
|||
Primary | ZOPRANOL Approved UseZOPRANOL is indicated for the treatment initiated within the first 24 hours of patients with acute myocardial infarction with or without signs and symptoms of heart failure. Launch Date9.6465597E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). | 1989 |
|
Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model. | 2009 Jun 9 |
|
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). | 2012 |
|
Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. | 2013 |
|
Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. | 2015 |
|
Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. | 2015 |
|
Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial. | 2015 |
|
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability. | 2016 Jul 5 |
Sample Use Guides
The usual effective dose in hypertension is 30 mg/day (in patients without volume or salt depletion) and the starting dose is 7.5 or 15 mg/day (in patients with volume or salt depletion). In acute myocardial infarction the treatment scheme is the following: 7.5 mg every 12 h (1st and 2nd day); 15 mg every 12 h (3rd and 4th day); 30 mg every 12 h (from 5th day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.nevapress.com/cdr/full/17/2/115.pdf
Zofenopril (36 uM) significantly increased coronary flow after 5 min of incubation with isolated rat hearts.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:36:49 UTC 2023
by
admin
on
Thu Jul 06 00:36:49 UTC 2023
|
Record UNII |
4G4WDK2YBS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
82602
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
75176-37-3
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
C065520
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
DB08766
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
6463
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
ZOFENOPRILAT
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
3034048
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
6599
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
4G4WDK2YBS
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
DTXSID50231443
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
SUB00171MIG
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
C95293
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY | |||
|
100000078772
Created by
admin on Thu Jul 06 00:36:49 UTC 2023 , Edited by admin on Thu Jul 06 00:36:49 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |